---
document_datetime: 2024-05-13 13:39:38
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vyxeos-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vyxeos-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.0119127
conversion_datetime: 2025-12-27 14:43:38.47964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vyxeos liposomal

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0043              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 23/04/2024                          |                                             | SmPC                             |           |
| IB/0042/G            | This was an application for a group of variations.                                                                                        | 10/04/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.z - Quality change - Active substance - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     |                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IA/0044/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                             | 05/04/2024 | n/a |                      |
| IA/0041/G | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change process                                                                                                                                   | 14/12/2023 | n/a | in the manufacturing |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                          |            |            |                                  |                                                                                                                                                                                                                                                                                |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0040           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                            | 20/10/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                                |
| R/0037              | Renewal of the marketing authorisation.                                                                                                                                                       | 30/03/2023 | 05/06/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vyxeos liposomal in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0039             | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 12/05/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                                |
| PSUSA/10701 /202208 | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                       | 16/03/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                              |
| IB/0033             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                  | 20/12/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                                |
| IA/0038             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                    | 11/11/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0036/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                            | 10/11/2022   | 05/06/2023   | SmPC   |                      |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|----------------------|
| IA/0034/G   | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 17/10/2022   | n/a          |        | procedure            |
| IB/0032     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                        | 13/10/2022   | n/a          |        |                      |
| II/0030     | Update of sections 4.2, 4.4 and 5.2 of the SmPC to amend information and delete the existing warning for patients with renal impairment based on the final results from study CPX351-102 (PMR2): a phase 1, open-label, PK and safety study to evaluate the potential impact of renal impairment on the safety of CPX-351                                                                                                                     | 21/07/2022   | 05/06/2023   | SmPC   | pharmacokinetics and |

<div style=\"page-break-after: always\"></div>

|           | (Daunorubicin and Cytarabine) liposome for injection treatment in adult patients with hematologic malignancies. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------|
| IB/0031/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.III.1.a.5 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate of a non-sterile AS that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed endotoxin free | 05/07/2022 | n/a | to be |
| II/0028/G | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change                                                                                                                                                                                                                                                                                                                               | 12/05/2022 | n/a |       |

<div style=\"page-break-after: always\"></div>

|                     | outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                       |                                                                                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------|
| II/0018/G           | This was an application for a group of variations. Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC to include relevant information in paediatric patients based on results from the paediatric clinical study AAML1421. The Package leaflet is updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 24/03/2022 | 02/06/2022 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Vyxeos Liposomal-H- discussioC-0004282-II-0018'            |
| IB/0029/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                              | 22/03/2022 | 02/06/2022 | SmPC                  | PI was updated to reflect extension of shelf life of finished product from 24 months to 30 months |
| PSUSA/10701 /202108 | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/03/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                 |
| II/0017             | Submission of a final CSR for post-marketing observational study of Vyxeos liposomal to assess the incidence of infusion-related reactions in adult                                                                                                                                                                                                                                                                                                                                                             | 02/12/2021 | n/a        |                       |                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | patients. The primary objective of this study is to assess the nature, incidence, and severity of infusion-related reactions during and for up to one day following the last infusion of a five-day induction course in patients treated with the product. The secondary objective is to assess this information during and for up to one day following the last infusion of a five-day induction course in patients treated with Vyxeos. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0026/G | This was an application for a group of variations. B.II.f.z - Stability of FP - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                             | 29/11/2021 | n/a |
| IB/0025   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/10/2021 | n/a |
| IA/0024/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/07/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|           | procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0023/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 25/05/2021 | n/a |
| IA/0022/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/04/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                 |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0021/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits | 11/03/2021 | n/a |
| II/0019   | B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                                                                                                                                                                                                                                                                                                     | 11/03/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| PSUSA/10701 /202008   | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                                                                                                                                                                                                                         | 11/03/2021   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                  | 06/01/2021   | 02/06/2022 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0014               | Update of the section 5.1 of the SmPC to reflect the 5-years overall survival data from the Follow-Up Phase of the Phase 3 Study CPX310-301. Additionally, the MAH has introduced minor editorial changes in the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                          | 26/11/2020   | 02/06/2022 | SmPC, Annex II and PL | SmPC new text 60 Month Follow-up phase of Study 301, a Phase 3 randomised, multicentre, open-label, parallel-arm, superiority study which evaluated Vyxeos liposomal vs. a standard combination of cytarabine and daunorubicin (7+3) in 309 patients between 60 to 75 years of age with untreated high-risk AML. The 60-month overall survival rate was higher for the Vyxeos treatment arm (18%) versus the 7+3 treatment arm (8%); the hazard ratio was 0.70 (95% CI: [0.55, 0.91]). For more information, please refer to the Summary of |
| II/0012/G             | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 10/09/2020   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| PSUSA/10701 /202002   | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/09/2020   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IA/0013/G             | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 06/07/2020   | n/a   |                                     |
| IAIN/0010             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/03/2020   | n/a   |                                     |
| PSUSA/10701 /201908   | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/02/2020   | n/a   | PRAC Recommendation - maintenance   |
| IA/0009               | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/01/2020   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                |            |            |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0008/G           | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 10/01/2020 | n/a        |                        |                                   |
| IAIN/0007           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                | 30/10/2019 | n/a        |                        |                                   |
| IAIN/0004           | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                       | 25/10/2019 | 28/08/2020 | SmPC, Labelling and PL |                                   |
| PSUSA/10701 /201902 | Periodic Safety Update EU Single assessment - daunorubicin / cytarabine                                                                                                                                                                                                                                                                               | 05/09/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0003             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                        | 23/08/2019 | 28/08/2020 | SmPC and PL            |                                   |
| IA/0001             | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved                                                                                                                                                                                                       | 29/03/2019 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| manufacturer   |
|----------------|